{"name": "Amarin",
 "permalink": "amarin",
 "crunchbase_url": "http://www.crunchbase.com/company/amarin",
 "homepage_url": "http://www.amarincorp.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "+353 (0)1 6699 020",
 "description": "",
 "created_at": "Thu Aug 19 02:14:58 UTC 2010",
 "updated_at": "Sun Feb 06 20:06:47 UTC 2011",
 "overview": "\u003Cp\u003EAmarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin\u00e2\u20ac\u2122s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides (\u0026gt;500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarin\u00e2\u20ac\u2122s cardiovascular programs capitalize on Amarin\u0026#8217;s expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease.\nAmarin is headquartered in Dublin, Ireland, and has its research and development headquartered in Mystic Connecticut, USA.  Amarin is listed in the U.S. on NASDAQ (ticker: AMRN) \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       42],
      "assets/images/resized/0009/8414/98414v1-max-150x150.png"],
     [[192,
       55],
      "assets/images/resized/0009/8414/98414v1-max-250x250.png"],
     [[192,
       55],
      "assets/images/resized/0009/8414/98414v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Colin",
      "last_name": "Stewart",
      "permalink": "colin-stewart",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "John",
      "last_name": "Thero",
      "permalink": "john-thero",
      "image": null}},
   {"is_past": false,
    "title": " Chief Medical Officer ",
    "person":
     {"first_name": "Dr.",
      "last_name": "Declan Doogan",
      "permalink": "dr-declan-doogan",
      "image":
       {"available_sizes":
         [[[113,
            150],
           "assets/images/resized/0002/6336/26336v2-max-150x150.png"],
          [[189,
            250],
           "assets/images/resized/0002/6336/26336v2-max-250x250.png"],
          [[231,
            304],
           "assets/images/resized/0002/6336/26336v2-max-450x450.png"]],
        "attribution": "\u003Cp\u003EDeclan Doogan\u003C/p\u003E"}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "First Floor, Block 3",
    "address2": "The Oval, Shelbourne Road",
    "zip_code": "",
    "city": "Ballsbridge, Dublin 4",
    "state_code": null,
    "country_code": "IRL",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "reporting positive, statistically significant top-line results from its first Phase 3 clinical trial of lead drug candidate AMR101",
    "stoned_year": 2010,
    "stoned_month": 11,
    "stoned_day": 29,
    "source_url": "http://www.masshightech.com/stories/2010/11/29/daily9-Amarin-treatment-for-high-triglycerides-shows-progress-in-trials.html",
    "source_text": null,
    "source_description": "Amarin treatment for high triglycerides shows progress in trials",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Amarin",
      "permalink": "amarin"}},
   {"description": "has announced a planned $100.2 million financing stemming from a public offering of American Depositary Shares",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 7,
    "source_url": "http://www.masshightech.com/stories/2011/01/03/daily66-Amarin-expecting-100M-financing.html",
    "source_text": null,
    "source_description": "Amarin expecting $100M financing",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Amarin",
      "permalink": "amarin"}},
   {"description": "has announced a planned $100.2 million financing stemming from a public offering of American Depositary Shares",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 7,
    "source_url": "http://www.masshightech.com/stories/2011/01/03/daily66-Amarin-expecting-100M-financing.html",
    "source_text": null,
    "source_description": "Amarin expecting $100M financing",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Amarin",
      "permalink": "amarin"}},
   {"description": "has named Paul Huff, an industry veteran with cholesterol drug commercialization under his belt, as chief commercial officer",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 2,
    "source_url": "http://www.masshightech.com/stories/2011/01/31/daily31-Amarin-names-Huff-to-lead-cholesterol-drug-commercialization.html",
    "source_text": null,
    "source_description": "Amarin names Huff to lead cholesterol drug commercialization",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Amarin",
      "permalink": "amarin"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}